biostudies-literatureUnknown19(1)Cozzi-Lepri A<h4>Introduction</h4>Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce.<h4>Methods</h4>Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann-Whitney U test and Chi-square test. A logistic regression model was used to compare participants' characteristics by treatment group. Kaplan-Meier analysis was used to estimate the cumulative risk of virological failure (VF, two consecutive values > 50 copies/mL).<h4>Results</h4>1,355 PLWH who started a RPV-based regimen (11% ART-naïve), as well as 333 initiating an EFV-containing regimen were included. Participants who staAIDS research and therapy38https://www.ebi.ac.uk/biostudies/studies/S-EPMC9357334biostudies-literatureObservational cohort study of rilpivirine (RPV) utilization in Europe.PMC9357334Wiese LParedes RMilinkovic ARanin JHoffmann CLaguno MDe Wit SKhromova IReiss PGrzeszczuk AGutierrez MKronborg GJablonowska EKnysz BDomingo PStephan CLundgren JDegen OEdwards SRojas JOstergaard LFatkenheuer GMiro JMHadziosmanovic VMaeland ATrofimova TYakovlev ASchmid PPai HNeesgaard BReikvam DHMachala LKuzovatova EElbirt DPuig JBogner JGirard PMFurrer HSzlavik JPradier CPaduta DSchmied BKamerys JSambeat ACozzi-Lepri AMocroft ALaporte JMMitsura VMMozer-Lisewska ILlibre JMVdoushkina ENielsen LNAksak-Was BSantos JRFlisiak RHarxhi AStellbrink HJEuroSIDA Study GroupSedlacek DFontas EFlamholc LOprea CMoreno SCallau PUzdaviniene VZagalo AKundro MMateo GMSvedhem VOrkin CPhillips AMClarke AJohansen ISBruun JWinston ABlanco JLStefan CDragas SVan Eygen VBattegay MSzetela BMaciejewska KMularska EDelforge MJou ACalmy APeters LBorodulina EWojcik KKarpov IJilich DTomazic JBegovac JStaub TPaduto DKuznetsova AMikhalik JSonnerborg AInglot MDuvivier CGarcia FTrajanovska JBenfield TTrofimora TZilmer KGerstoft JMartinez ESluzhynska MJohnson AMPaissios NMallolas JPelchen-Matthews AParczewski MRockstroh JLeen CViard JPMartinez-Rebollar MBrannstrom JAdamis GSambatakou HDel Campo SJohnson AKusejko KVassilenko AClumeck NBeniowski MPedersen CThalme AMoller NFLosso MSmidt JAho IChkhartishvili NRozplochowski BRadoi RBakowska ESimons EWeber RfalseObservational cohort study of rilpivirine (RPV) utilization in Europe.<h4>Introduction</h4>Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce.<h4>Methods</h4>Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann-Whitney U test and Chi-square test. A logistic regression model was used to compare participants' characteristics by treatment group. Kaplan-Meier analysis was used to estimate the cumulative risk of virological failure (VF, two consecutive values > 50 copies/mL).<h4>Results</h4>1,355 PLWH who started a RPV-based regimen (11% ART-naïve), as well as 333 initiating an EFV-containing regimen were included. Participants who sta2022-01-01T00:00:00Z2022 Aug2025-04-18T16:55:45.111Z2025-02-19T02:27:09.659ZS-EPMC93573343593335210.1186/s12981-022-00457-0